<DOC>
	<DOCNO>NCT00789737</DOCNO>
	<brief_summary>The current study investigates Welchol monotherapy improve glycemic control subject Type 2 Diabetes Mellitus adequately control diet exercise alone . The study evaluate Welchol monotherapy Type 2 Diabetes Mellitus safe , well tolerate efficacious .</brief_summary>
	<brief_title>Welchol Monotherapy Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Male female subject &gt; = 18 year age ; Women childbearing potential ( WOCBP ) must use adequate method contraception detail protocol . Diagnosis Type 2 Diabetes Mellitus ; HbA1C &gt; = 7.5 % = &lt; 9.5 % screening ; Fasting Cpeptide &gt; 0.5 ng/mL screening ; Drug na√Øve ( prior treatment OAD ) receive pharmacologic therapy diabetes 3 month period prior screen ; Clinically stable regard medical condition type 2 diabetes ; Concomitant medication must stable dos least 30 day prior enrollment , anticipated need adjustment study period ; Fasting glucose = &lt; 240 mg/dL randomization A history type 1 diabetes and/or history ketoacidosis ; History bowel obstruction ; History hypertriglyceridemiainduced pancreatitis ; Fasting serum triglyceride concentration &gt; 500 mg/dL ; History dysphagia , swallow disorder , gastroparesis , gastrointestinal ( GI ) motility disorder , major GI surgery ; History insulin use &gt; = 2 week duration previous 3 month total &gt; 2 month insulin therapy time prior screening ; Two fasting selfmonitored blood glucose ( SMBG ) level &gt; 240 mg/dL placebo leadin period . Previous treatment bile acid sequestrant , include Welchol within 3 month prior screen ; Body mass index ( BMI ) &gt; 40 kg/m2 ; Weight loss &gt; 3 % prior 3 month ; LDL &lt; 60 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>